1 Humoral and cellular response induced by a second booster of an

2 inactivated SARS-CoV-2 vaccine in adults.

3

Felipe Melo-González^{1,2,3#}, Constanza Méndez^{1,2#}, Hernán F Peñaloza^{1,2#}, Bárbara 4 M Schultz^{1,2#}, Alejandro Piña-Iturbe^{1,2}, Mariana Ríos^{1,2}, Daniela Moreno-Tapia^{1,2}, 5 6 Patricia Pereira-Sánchez^{1,2}, Diane Leighton^{1,2}, Claudia Orellana^{1,2}, Consuelo Covarrubias^{1,2}, Nicolás MS Gálvez^{1,2}, Jorge A Soto^{1,2,3}, Luisa F Duarte^{1,2}, Daniela 7 Rivera-Pérez^{1,2}, Yaneisi Vázquez^{1,2}, Alex Cabrera⁴, Sergio Bustos⁴, Carolina 8 9 Iturriaga⁵, Marcela Urzua⁵, María S Navarrete⁶, Álvaro Rojas⁶, Rodrigo Fasce⁷, Jorge Fernández⁷, Judith Mora⁷, Eugenio Ramírez⁷, Aracelly Gaete-Argel^{1,8}, Mónica 10 Acevedo^{1,8}, Fernando Valiente-Echeverría^{1,8}, Ricardo Soto-Rifo^{1,8}, Daniela 11 12 Weiskopf⁹, Alba Grifoni⁹, Alessandro Sette^{9,10}, Gang Zeng¹¹, Weining Meng¹¹, CoronaVac03CL Study Group, José V González-Aramundiz¹², Pablo A González^{1,2}, 13 Katia Abarca^{1,5}, Susan M Bueno^{*,1,2}, Alexis M Kalergis^{*,1,2,13}. 14

15

¹Millennium Institute on Immunology and Immunotherapy, Santiago, Chile. 16 17 ²Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile. ³Departamento 18 de Ciencias Biológicas, Facultad de Ciencias de la Vida, Universidad Andrés Bello, 19 20 Santiago, Chile. ⁴Flow Cytometry Facility, Facultad de Ciencias Biológicas, Pontificia 21 Universidad Católica de Chile, Santiago, Chile. ⁵Departamento de Enfermedades 22 Infecciosas e Inmunología Pediátrica, División de Pediatría, Escuela de Medicina, 23 Pontificia Universidad Católica de Chile, Santiago, Chile, ⁶Departamento de 24 Enfermedades Infecciosas del Adulto, División de Medicina, Escuela de Medicina,

Pontificia Universidad Católica de Chile, Santiago, Chile. ⁷Departamento de 25 Laboratorio Biomédico, Instituto de Salud Pública de Chile. ⁸Laboratorio de Virología 26 Molecular y Celular, Programa de Virología, Instituto de Ciencias Biomédicas, 27 Facultad de Medicina, Universidad de Chile, Santiago de Chile. ⁹Center for 28 29 Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA. ¹⁰Department of Medicine, Division of Infectious Diseases 30 31 and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA 92037, USA. ¹¹Sinovac Biotech, Beijing, China. ¹²Departamento de Farmacia, 32 Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, 33 34 Santiago, Chile. ¹³Departamento de Endocrinología, Facultad de Medicina, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. 35

36

37 ***Corresponding author:**

Alexis M Kalergis, Pontificia Universidad Católica de Chile. Av. Libertador Bernardo
O'Higgins Nº 340, Santiago 8331010, Santiago, Chile. Phone 56-2-6862846. Email:
akalergis@bio.puc.cl.

41 *Alternate corresponding author:

Susan M Bueno, Pontificia Universidad Católica de Chile. Av. Libertador Bernardo
O'Higgins Nº 340, Santiago 8331010, Santiago, Chile. Phone 56-2-6862846. Email:
sbueno@bio.puc.cl

45

46 ***These authors contributed equally to this work.**

47 Summary

The SARS-CoV-2 Omicron variant has challenged the control of the COVID-19 48 pandemic even in highly vaccinated countries. While a second booster of mRNA 49 vaccines improved the immunity against SARS-CoV-2, the humoral and cellular 50 51 responses induced by a second booster of an inactivated SARS-CoV-2 vaccine have 52 not been studied. In the context of a phase 3 clinical study, we report that a second booster of CoronaVac[®] increased the neutralizing response against the ancestral 53 virus yet showed poor neutralization against the Omicron variant. Additionally, 54 isolated PBMCs displayed equivalent activation of specific CD4⁺ T cells and IFN-y 55 56 production when stimulated with a mega-pool of peptides derived from the spike protein of the ancestral virus or the Omicron variant. In conclusion, a second booster 57 dose of CoronaVac[®] does not improve the neutralizing response against the 58 Omicron variant compared with the first booster dose, yet it helps maintaining a 59 robust spike-specific CD4⁺ T cell response. 60

61

Key words: CoronaVac[®], second booster dose, SARS-CoV-2, Omicron variant,
 humoral immunity, cellular immunity.

64 Introduction.

The development of vaccines that grant long-lasting protection against SARS-CoV-65 2 is essential to control the current COVID-19 pandemic. Although several vaccines 66 67 were developed in record time, three dynamic phenomena have prevented the global 68 control of the COVID-19 pandemic. First, the continuous emergence of SARS-CoV-69 2 variants of concern (VOCs), such as Omicron (BA.1, BA.2), and its subvariants 70 (BA.2.12.1, BA.4, BA.5) with high transmissibility and immune evasion profiles¹. Second, the waning of neutralizing antibodies in fully vaccinated subjects². Third, the 71 difficulties to mass producing and globally distributing enough vaccines or 72 73 implementing affordable and effective vaccination programs.

Several platforms have been used to develop vaccines against SARS-CoV-2³. Due 74 to their novelty, mRNA vaccines (BNT162b2 and mRNA-1273) have been the most 75 76 studied and are highly effective in protecting individuals from symptomatic infection, severe disease, and death^{4,5}. Inactivated virus-based vaccine, a more traditional 77 vaccine platform, has also been used to develop a SARS-CoV-2 vaccine. 78 79 CoronaVac[®], an inactivated vaccine developed by Sinovac Life Sciences Co., Ltd. (Beijing, China)⁶, has been administered so far in 52 countries⁷, showing a good 80 safety profile in the population⁸⁻¹⁰ and a robust immune protection against severe 81 disease, hospitalization, and death¹¹. 82

During a phase 3 clinical trial in Chile, our group demonstrated that a two-dose
vaccination schedule of CoronaVac[®] induced a strong neutralizing response and T
cell activation against SARS-CoV-2 in adults¹². Further studies from our laboratory
determined that fully vaccinated subjects with CoronaVac[®] showed a strong
production of neutralizing antibodies and IFN-γ production in stimulated peripheral

blood mononuclear cells (PBMCs) against different VOCs of SARS-CoV-2, such as
Alpha, Beta, Gamma, and Delta¹³.

Different studies have reported a reduction of the neutralizing response against
SARS-CoV-2 in immunized subjects with BNT162b2 and mRNA1273 vaccines¹⁴⁻¹⁶.
These studies also showed that a booster dose was required to keep an effective
neutralizing response against the ancestral SARS-CoV-2 (WT SARS-CoV-2) and
circulating variants at that time^{14,15,17}.

95 Consistently with the mentioned studies, our group reported a considerable 96 reduction of the neutralizing response five months after the administration of the 97 second dose of CoronaVac[®], response that was recovered after the administration 98 of a booster dose of CoronaVac^{®18}. Furthermore, the enhanced neutralizing 99 response initially detected against WT SARS-CoV-2 was effective against the Delta 100 variant, but showed reduced neutralization against the Omicron variant¹⁸, which is 101 currently the most prevalent variant of SARS-CoV-2 worldwide.

Although previous studies have shown that a second booster with BNT162b2 and 102 mRNA1273 vaccines would prevent the decrease of neutralizing antibodies and may 103 offer protection against symptomatic disease, severe disease, hospitalization, and 104 death caused by the Omicron variant^{4,19}, the effect of a second booster dose of 105 CoronaVac[®] in the humoral and cellular response against SARS-CoV-2, with special 106 107 emphasis on the Omicron variant, remains to be elucidated. In the present report, 108 we study the dynamics of the humoral and cellular immune responses in individuals that received a second booster of CoronaVac® 6 months after the administration of 109 a first booster of the same vaccine. Our data shows that a second booster of 110 CoronaVac[®] induces a strong production of antibodies with neutralizing capacities 111

- against WT SARS-CoV-2, although it has poor activity against the Omicron variant.
- 113 We also show that a second booster dose of CoronaVac[®] is required to keep high
- 114 levels of SARS-CoV-2-specific CD4⁺ T cells in circulation that are reactive against
- the WT SARS-CoV-2, the Delta, and the Omicron variants.
- 116

117 Results.

118 **1.** <u>Participants, sampling and experimental applications included in the study.</u>

From a total of 2,302 individuals enrolled in the clinical trial CoronaVac03CL 119 (clinicaltrials.gov #NCT04651790) in Chile (November 2020- to current date) 120 121 ^{12,13,18,20,21}, 138 fully vaccinated subjects with CoronaVac[®] (0-28 schedule) that 122 received two booster doses were initially considered for this study (Fig 1A). After the 123 exclusion of 51 subjects due to SARS-CoV-2 infection during the trial or missing 124 data, longitudinal analyses of the humoral response were performed in up to 87 125 subjects, whereas the cellular response was studied in a subgroup of 46 subjects 126 (Fig 1A).

Blood samples were collected before vaccination (T1), four to seven weeks after the second dose (T2), at least 9 weeks before the first booster dose (T3), three to six weeks after the first booster dose (T4), at least nine to cero weeks before the second booster dose (T5) and four to nine weeks after second booster dose (T6) (Fig 1B).

131

132 2. <u>Humoral response against SARS-CoV-2 induced by a second booster dose</u> 133 of CoronaVac[®].

Neutralizing response of serum was evaluated by three different and complementary methodologies, surrogate virus neutralization test (sVNT), conventional virus neutralization test (cVNT), and pseudotype virus neutralization test (pVNT) (see method section). Consistently with previous studies^{12,18}, individuals vaccinated with two doses of CoronaVac[®] presented a significant increase in neutralizing antibodies against WT SARS-CoV-2 four weeks after the administration of the second dose when compared with the pre-immune serum (T1 vs. T2) (16.8 vs. 199.7 GMUs

p<0.0001; 2.9 vs. 21.1 GMTs p<0.0001) (Fig. 2A-B, supplementary tables 1 and 3). 141 142 Then, a significant reduction in the neutralizing antibody against SARS-CoV-2 was observed three to five months (15-20 weeks) after the administration of the second 143 dose when compared with four weeks after the administration of the second dose 144 145 (T2 vs. T3) (199.7 vs. 53.1 GMUs p<0.0001; 21.1 vs. 10.0 GMTs p<0.0001) (Fig. 2A-B supplementary table 1 and 3). Consistently with other studies¹⁴⁻¹⁶, the 146 147 administration of a first booster dose resulted in a rapid improvement of the neutralizing response against WT SARS-CoV-2 after 4 weeks when compared with 148 149 at least nine weeks before its administration (T3 vs. T4) (53.1 vs. 586.0 GMUs 150 p<0.0001; 10.0 vs. 95.1 GMTs p<0.0001) (Fig. 2A-B supplementary table 1 and 3). 151 Interestingly, the neutralizing capacity against WT SARS-CoV-2 observed six months (24 weeks) after the administration of the first booster dose was partially 152 reduced in comparison to the response detected 4 weeks after the administration of 153 the first booster dose (T5 vs. T4) (220.4 vs. 586.0 GMUs p<0.001; 54.9 vs. 154 155 95.1GMTs p>0.05) (Fig. 2A-B, supplementary table 1 and 3). Finally, 4 to 9 weeks after the administration of a second booster dose, an increase in the neutralizing 156 response against WT SARS-CoV-2 was observed when compared with the time 157 158 before the administration of the second booster dose (T5 vs. T6) (220.4 vs. 549.2 GMUs p<0.001; 54.9 vs. 149.3 GMTs p>0.05) (Fig. 2A-B, supplementary table 1 and 159 160 3). Importantly, the neutralization response against WT SARS-CoV-2 observed after 161 the administration of the second booster dose was not significantly higher than the response induced by the first booster dose (T4 vs. T6) (586.0 vs. 549.2 GMUs 162 p>0.05; 95.1 vs. 149.3 GMTs p>0.05) (Fig. 2A-B, supplementary table 1 and 3). This 163 data indicates that a second booster dose of CoronaVac[®] is required to keep high 164

165 levels of neutralizing antibodies against WT SARS-CoV-2. Moreover, given that the 166 neutralization observed after the first and the second booster dose was equivalent, 167 we hypothesize that the neutralizing response against SARS-CoV-2 induced by the 168 administration of the first booster dose of CoronaVac[®] has reached a peak of 169 neutralizing antibodies that are sustained by the administration of a second booster 170 dose.

The administration of the second booster dose of CoronaVac[®] kept the seropositivity rate higher than 96% for both sVNT and cVNT, with seroconversion levels of 93.1% and 95.2% for sVNT and cVNT, respectively (supplementary table 3).

174 Next, we evaluated whether the neutralizing antibodies generated after the second 175 booster dose was effective against the Delta (B.1.617.2) and the Omicron 176 (B.1.1.529) variants. Although serum from vaccinated individuals collected four weeks after the second booster dose presented a mildly reduced ability to neutralize 177 WT SARS-CoV-2 when compared with samples collected four weeks after the first 178 179 booster dose (Fig 2C), the neutralization response against WT SARS-CoV-2 was significantly higher when compared with the Delta (B.1.617.2) and especially with 180 the Omicron (B.1.1.529) variants (33.0 vs. 3.7 GMTs p<0.001, 8.9-fold reduction) 181 182 (Fig 2C, supplementary table 2). Moreover, as compared with the first booster dose, the administration of the second booster dose of CoronaVac[®] did not significantly 183 184 impact the seropositivity rate (93.1% vs. 94.3%) and the seroconversion rate (80.5% 185 vs. 67.8%) against the Delta variant, although it slightly increased the seropositivity rate (17.2% vs. 32.2%) and the seroconversion rate (4.6% vs. 18.4%) against the 186 Omicron variant (supplementary table 4). 187

Neutralization against the Omicron variant was also confirmed with a pseudotypebased neutralization assay in sixty subjects (supplementary figure 1) and indicate that a second booster dose of CoronaVac[®] maintains high neutralizing antibody levels against WT SARS-CoV-2 that reduced neutralization capacity against the Omicron variant.

193

3. <u>Cellular response against SARS-CoV-2 induced by a second booster dose</u> of CoronaVac®.

We next evaluated the cellular response in a subgroup of fully vaccinated volunteers 196 197 (n=46) that received two booster doses of CoronaVac[®] (Fig 1A). PBMCs were stimulated with mega-pools of peptides of SARS-CoV-2 theoretically able to activate 198 CD4⁺ T cells (S+R) and CD8⁺ T cells (CD8A+B)²² and SARS-CoV-2-specific 199 200 OX40⁺CD137⁺CD4⁺T cells (AIM⁺CD4⁺ T cells), as well as SARS-CoV-2 specific CD69⁺CD137⁺CD8⁺ T cells (AIM⁺CD8⁺ T cells) were quantified by flow cytometry. 201 Our data show that the activation of SARS-CoV-2-specific AIM⁺CD4⁺ T cells was 202 203 higher after the second dose of CoronaVac® in comparison with the pre-immune sample (0.13% vs. 0.33% p=0.0241) (Fig. 3A; supplementary table 5). Although no 204 significant increase in the percentage of AIM⁺CD4⁺ T cells was observed after the 205 administration of the first or the second booster dose, the activation of AIM+CD4+ T 206 207 cells remained stable over time, showing only a significant decrease 4-6 months 208 after the first booster dose, that is successfully recovered after the administration of the second booster dose (Fig 3A, supplementary table 5). Further, we did not detect 209 210 a significant activation of SARS-CoV-2-specific AIM+CD8+ T cells in fully vaccinated

volunteers with CoronaVac[®] after the administration of the first or the second booster
dose (Fig. 3B; supplementary table 5).

Next, we evaluated the production of IFN-y in stimulated-PBMCs by ELISPOT (Fig. 213 3C-D, supplementary table 5). The production of IFN-v by stimulated PBMCs was 214 215 consistent with the activation of CD4⁺ and CD8⁺ T cells in subjects that received a second booster dose of CoronaVac[®]. A significant increase in IFN-v⁺ SFCs was 216 observed in PBMCs stimulated with MP-S+R after the second dose of CoronaVac® 217 (4.1-fold increase in PBMCs stimulated with MP-S+R p=0.0004) (Fig 3C, 218 supplementary table 5). Moreover, the increase in IFN-y+SFCs observed after the 219 second dose of CoronaVac[®] remained stable over time and was also observed after 220 221 the administration of the first and the second booster dose (Fig 3C, supplementary 222 table 5). In contrast, no significant changes in IFN-v⁺SFCs were observed in PBMCs 223 stimulated with MP-CD8A+B after the second dose of CoronaVac® (1.5-fold increase in PBMCs stimulated with MP-CD8A+B p>0.05) (Fig. 3D) nor after the administration 224 of a first or second booster of CoronaVac[®] (Fig 3D, supplementary table 5). 225

226 Even though we did not detect a significant increase in the frequency of AIM⁺CD4⁺T 227 cells after the administration of the first or the second booster doses of CoronaVac[®]. 228 we observed important changes in the frequency of volunteers with detectable levels of AIM+CD4+T cells over time. Whereas 13.0% (6/46) of volunteers presented 229 230 detectable levels of SARS-CoV-2-specific AIM+CD4+T cells before vaccination, two 231 doses of CoronaVac[®] increased this frequency to 34.8% (16/46), frequency that was further increased after the first booster of CoronaVac[®], where 65.2% (30/46) of 232 subjects showed detectable levels of SARS-CoV-2-specific AIM⁺CD4⁺T cells (Table 233 1). Consistently, the frequency of subjects whose PBMCs produced IFN-γ after 234

stimulation with MP-S+R increased after the administration of CoronaVac[®], starting 235 236 from 17.4% (8/46) before vaccination to 47.8% (22/46) after two doses of CoronaVac[®] and to 67.4% (31/46) after the first booster of CoronaVac[®] (Table 1). 237 Interestingly, the second booster of CoronaVac[®] (45.7%, 21/46) did not increase the 238 239 frequency of volunteers that have specific SARS-CoV-2 specific AIM+CD4+T cells in 240 circulation as compared with the first booster dose, although it seems that it is 241 required to prevent the decrease in frequency of volunteers with SARS-CoV-2 specific AIM+CD4+T cells observed right before the administration of the second 242 243 booster dose (41.3%, 19/46) (Table 1). Moreover, the second booster of 244 CoronaVac[®] did not significantly affect the progressive decrease of IFN-y production 245 by stimulated PMBCs (50% 23/46) in comparison with the response induced by the 246 first booster dose, where 67.4% of the volunteers (31/46) showed production IFN-v 247 production (Table 1).

A mild increase in the frequency of volunteers that showed AIM⁺CD8⁺ T cells after 248 two doses of CoronaVac[®] (34.8%, 16/46) was observed as compared to before 249 250 vaccination (13.0%, 6/46) (Table 1). Even though the administration of a first booster of CoronaVac[®] (34.8%, 16/46) was necessary to keep the frequency of volunteers 251 252 with detectable levels of SARS-CoV-2-specific AIM+CD8+T cells, the second booster 253 dose (26.1%, 12/46) did not prevent the reduction of the positivity of SARS-CoV-2-254 specific AIM⁺CD8⁺ T cells in our cohort (Table 1). In addition, when PBMCs were 255 stimulated with MP-CD8A+B, the frequency of volunteers that showed IFN-y production reached a peak of 17.4% (8/46) right before the administration of a 256 second booster that slightly decreased after the administration of the second booster 257 258 dose of CoronaVac[®] (13.0%, 6/46) (Table 1).

medRxiv preprint doi: https://doi.org/10.1101/2022.08.22.22279080; this version posted August 29, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

259 Finally, we evaluated the activation of AIM⁺CD4⁺ T cells and IFN- γ^+ production by 260 PBMCs in response to a mega-pool of peptides derived from the Spike protein of the Delta and the Omicron variants by flow cytometry and ELISPOT, respectively, four 261 weeks after the administration of the first booster dose and four weeks after the 262 263 administration of the second booster dose. Our data show that the activation 264 AIM⁺CD4⁺ T cells and IFN-v⁺SFCs were equivalent when PBMCs were stimulated 265 with a mega-pool of peptides derived from the WT SARS-CoV-2, the Delta, or the Omicron variants (Fig. 3E-F) and no major differences were detected in the 266 267 activation of AIM⁺CD4⁺ T cells and IFN-y⁺SFCs in PBMCs, between the first and the 268 second booster dose against each of these variants (Fig. 3E-F). Importantly, we 269 detected a small decrease in the percentage of subjects that presented Spike-270 specific CD4⁺AIM⁺ against the WT. Delta and Omicron variants after the second 271 booster compared with after the first booster dose (supplementary table 6). 272 Importantly, the frequency of volunteers whose PBMCs produced IFN-y remained 273 constant after the stimulation of MP-S from WT and the Delta variant and only showed a mild decreased after MP-S from the Omicron variant (supplementary table 274 6). 275

These data show that CoronaVac[®] induces a robust CD4⁺ T cells response able to react against the Delta and the Omicron variants that remains high after a second booster dose even though it showed a progressive decrease in its positivity. Although the humoral immunity against Delta and Omicron variants decreases, cellular immunity remains robust across time and reacts against these variants.

281

282 **Discussion**.

In line with other reports^{4,19}, our data show that a second booster dose of CoronaVac[®] restores the neutralizing response against the RBD of SARS-CoV-2 to similar levels reached after the administration of the first booster dose.

Neutralizing antibodies induced by vaccines has been acknowledged as the first line of defense against SARS-CoV-2 infection. However, follow-up studies have shown that fully vaccinated individuals show a gradual decrease in their levels of circulating neutralizing antibodies over time^{14-16,18}. This response can be restored with the administration of a booster dose^{14,18}, and some studies have even shown that a second booster dose may grant better protection against severe disease, hospitalization, and death due to COVID-19^{4,23}.

Our data show that despite a second booster dose induces the production of 293 294 neutralizing antibodies against WT SARS-CoV-2, these antibodies only weakly neutralized the Omicron variant. These results are consistent with other studies that 295 296 show that the Omicron variant and its subvariants are incredibly efficient in evading 297 serum neutralization from individuals who have received one or two booster doses^{1,19,24}. Therefore, it is unlikely that nowadays, the increased protection against 298 299 severe disease, hospitalization, and death granted by a second booster dose could 300 be mainly mediated by the action of neutralizing antibodies.

Nonetheless, we detected a slight but non-significant increment of 1.6-fold change in the neutralization of WT SARS-CoV-2 between four weeks after the first booster dose and four weeks after the second booster dose by cVNT (Fig 1B). This modest increase in WT SARS-CoV-2 neutralization granted by the second booster was not observed through sVNT (Fig 1A, C). sVNT directly neutralizes the binding of the RBD with ACE-2, neglecting the potential role of neutralizing antibodies against other 307 portions of the Spike protein and even against other viral proteins. Therefore, it is 308 possible that neutralizing antibodies against other domains of the Spike protein and 309 potentially against other viral proteins such as the membrane or the nucleocapsid 310 proteins not considered in the sVNT approach may actively participate in viral 311 neutralization.

The second layer of protection corresponds to the proliferation, activation, and activity of T cells. Currently, the leading hypothesis regarding the protective mechanism of SARS-CoV-2 vaccines against severe disease and death relies on the induction of long-lasting T cells responses rather than on the availability of circulating neutralizing antibodies^{25,26}.

317 In the present study, we report that the activation of AIM⁺CD4⁺ T cells in fully vaccinated individuals remains detectable over time after administering a first and a 318 319 second booster of CoronaVac[®]. In addition, one study has identified a robust activation of CD4+OX40+CD137+ T cells, CD4+OX40+sCD40L+ T cells, and follicular 320 CD4⁺CXCR5⁺OX40⁺ T cells in individuals that received two doses of mRNA-1273, 321 322 BNT162b2 or NVX-CoV2373 (Novavax), and one dose of Ad26.COV2.S (Janssen)²⁷. Our data is consistent with these findings, although the ability of 323 CoronaVac[®] to induce a robust memory T cell response remains to be elucidated. 324

325 On the other hand, it has been reported a significant expansion and activation of 326 IFN- γ^+ CD8⁺ T cells in PBMCs of individuals vaccinated with two doses of mRNA-327 1273, BNT162b2, and NVX-CoV2373, and one dose of Ad26.COV2.S²⁷. However, 328 we did not find a significant increase in CD8⁺AIM⁺ T cells (Fig. 3B) nor a significant 329 increase in IFN- γ production (Fig 3D) in stimulated PBMCs from subjects immunized 330 with CoronaVac[®] when compared with the pre-immune sample. In contrast, previous

studies have described that two doses of CoronaVac[®] induce the production of IFN- γ by CD8⁺ T cells^{28,29}. Therefore, more exhaustive studies aimed to understand how CoronaVac[®] influences the expansion and activation of CD8⁺ T cells, memory T cells, and memory B cells are required to fully elucidate the protective mechanisms driven by CoronaVac[®] in immunized adults, children, and the elderly.

336 Four interesting findings emerge from our study. First is the presence of neutralizing 337 antibodies (Fig 2A-B) in pre-immune samples of some individuals. Most of the preimmune neutralizing response was identified against the infective virus. 338 Asymptomatic SARS-CoV-2 infections³⁰ and antibodies generated against non-339 spike proteins of seasonal coronaviruses³¹ could explain this response, although 340 341 serologic studies are needed to confirm these hypotheses. Moreover, our data show 342 that whereas 6/46 of the analyzed volunteers presented SARS-CoV-2-specific AIM⁺CD4⁺ or AIM⁺CD8⁺ T cells before the administration of CoronaVac[®]; 25/46 and 343 34/46 volunteers did not present AIM⁺CD4⁺ or AIM⁺CD8⁺ T cells, respectively after 344 the second booster of CoronaVac[®]. A previous study has shown a possible cross-345 reactive response of seasonal coronaviruses-specific T cells against SARS-CoV-2²². 346 and it is likely the reason why some volunteers presented SARS-CoV-2 specific T 347 348 cells before vaccination, although asymptomatic infections cannot be ruled out. 349 Further studies are needed to fully understand the factors involved in the generation 350 and maintain of an efficient T cell response and the effect on vaccine-induced 351 protection.

Finally, our data show that the effect on humoral and cellular responses of the second booster dose, is different when compared with the effect of the first booster dose. Whereas our data and several other studies have shown that a first booster

increase the humoral and cellular response against SARS-CoV-2^{14,15,17,18}, the 355 356 administration of a second booster dose seems to maintain the global neutralizing response, the activation of AIM⁺CD4⁺ T cells and IFN-y by stimulated PBMCs 357 358 against WT SARS-CoV-2 and the Omicron variant reached by the first booster dose. 359 Importantly, in terms of the percentage of individuals able to respond against the 360 virus, our data show that even though the second booster restores seropositivity and 361 seroconversion to equivalent levels observed after the first booster dose, it seems 362 to be insufficient to restore the frequency of volunteers with detectable SARS-CoV-363 2-specific AIM⁺CD4⁺ T cells and IFN-y by stimulated PBMCs to levels observed after 364 the first booster dose.

365 Controlling the COVID-19 pandemic requires multiple efforts to prevent severe 366 disease and death of infected patients and reduce viral infection and circulation in 367 the community.

The data provided in this report and other studies suggest that CoronaVac[®] and other current vaccines effectively protect the population from severe disease, hospitalization, and death. However, the immune response induced by these vaccines poorly neutralizes the circulating SARS-CoV-2 variants and cannot prevent viral infection.

Therefore, new strategies that include the design of new vaccines that target the current variants, new types of vaccines that enforce immunity in the upper respiratory tract, and global vaccine distribution programs are essential to control and end the COVID-19 pandemic.

377 Methods.

378 Volunteers and sample collection

379 Blood samples were obtained from volunteers recruited in the clinical trial

380 CoronaVac03CL (clinicaltrials.gov #NCT04651790) in Chile (November 2020- to

381 current date)^{12,13,18,20,21}.

382 Of the 2,302 individuals enrolled at baseline, 409 subjects entered the study and received two doses with the homologous CoronaVac® 0-28 schedule, and 138 383 subjects ended up receiving two booster doses of CoronaVac[®]. In addition, blood 384 samples from 87 subjects were collected from before vaccination (T0) to up to four-385 386 nine weeks after the second booster administration (T6). Volunteers who did not 387 have a blood sample at some of the planned times of the study or who had previously exceeded the definitive time limit and volunteers who had developed SARS-COV-2 388 during the study were excluded (Figure 1A). 389

390 Volunteers received two doses of CoronaVac® (3 µg or 600SU of inactivated SARS-

CoV-2 inactivated in the presence of alum adjuvant) in a four-week interval (0-28 days), a booster dose five months after the second dose, and a second booster dose 6 months after the first (Figure 1B). Blood samples collected 6 times were analyzed: T1: Pre-immune, T2: 2nd dose + 4 weeks (+3 weeks), T3: before the administration of the third dose (-9 weeks), T4: at 4 weeks (±2 weeks) after the third dose, T5: before the administration of the fourth dose (-9 weeks), T6: and at 4 weeks (±5 weeks) after the fourth dose (T6), and vaccination schedule.

398

399 Experimental procedures

medRxiv preprint doi: https://doi.org/10.1101/2022.08.22.22279080; this version posted August 29, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

400 Neutralizing antibodies against RBD of WT SARS-CoV-2 were measured in the 401 serum of 87 volunteers recruited in the clinical trial CoronaVac03CL (clinicaltrials.gov #NCT04651790). Briefly, blood samples were obtained at T1, T2, T3, T4, T5, and 402 T6. Neutralization of SARS-CoV-2 RBD by circulating antibodies at each time point 403 404 was evaluated by a surrogate virus neutralization test (sVNT) (Genscript Cat#L00847-A)¹². The antibody levels in international units per mL (IU/mL) were 405 406 estimated by interpolating the sVNT absorbance data in the standard curve made 407 with the WHO International Standard 20/136, using the 4-parameter Logistic model. 408 In addition, sVNT was used to evaluate the neutralizing capacity of the tools against 409 the Delta and Omicron variants, the RBDs for the S protein of SARS-CoV-2 for Delta 410 (Cat# Z03516) and Omicron B.1.1.529 (Cat#Z03730) in 87 volunteers.

Infective virus neutralization assays were performed as previously described^{12,18}. 411 412 Briefly, Vero E6 cells (4×10⁴ cells/well) were plated in 96-well plates. 100 µL of 33782CL-SARS-CoV-2 (100 TCID₅₀) were incubated with serial dilutions of heat-413 414 inactivated individual serum samples (dilutions of 1:4, 1:8, 1:16, 1:32, 1:64, 1:128, 415 1:256, and 1:512) for 1h at 37 °C. Then, the mix was added to the 96-well plates with the Vero E6 cells, and the cytopathic effect was analyzed after 7 days. A serum 416 417 sample from uninfected patients (negative control) and a neutralizing COVID-19 418 patient serum sample (positive control) was used for each test.

419 A pseudotyped virus neutralization test (pVNT) assay was performed to assess the 420 capacity of the antibodies against SARS-CoV-2 VOC in samples from forty-eight 421 volunteers as previously reported³². Briefly, a HIV-1 backbone expressing firefly 422 luciferase as a reporter gene and pseudotyped with the SARS-CoV-2 spike 423 glycoproteins (HIV-1-SΔ19) from lineage B.1 (D614G) and variant Omicron (A67V,

ΔH69-V70, T95I, Y145D, ΔG142 -V143- Y144, ΔN211, EPE 213-214, G339D,
S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R,
G496S, Q498R, N501Y, T547K, D614G, H655Y, N679K, P681H, N764K, N865K,
Q954H, N969K, L981F) was prepared. Serum samples were diluted, and the
estimation of the ID80 was obtained using a 4-parameter nonlinear regression curve
fit measured as the percent of neutralization determined by the difference in average
relative light units (RLU) between test samples and pseudotyped virus controls.

431 Seropositivity is considered when titers are increased compared to pre-immune
432 condition³³. On the other hand, seroconversion was thought to be when the titer of
433 neutralizing results increased 4 times with respect to the pre-immune condition.

434 The expression of Activation-Induced Markers (AIM) by T cells and the number of 435 Spot Forming Cells (SFC) for IFN-y were determined by ELISPOT and were evaluated by flow cytometry in a subgroup of 46 volunteers as previously 436 described^{12,13,18}. Briefly, PBMCs were stimulated with mega-pools (MPs) of peptides 437 derived from SARS-CoV-2: MP-S, MP-R, MP-CD8-A, MP-CD8-B, Delta, and 438 Omicron for 24h or 48h for flow cytometry and ELISPOT respectively. Then, 3-5 x 439 10⁵ cells were plated and stimulated with MP-S, MP-R, MP-CD8A, MP-CD8B, 440 441 DMSO (negative control), or Phorbol-12-acetate (1.62 mM)(Sigma, #P8139)/Ionomycin (0.6mM) (Sigma #I0634)²². Antibodies used to identify 442 443 AIM⁺CD4^{+,} and AIM⁺CD8⁺ T cells by flow cytometry are detailed in supplementary 444 table 7. Samples were analyzed in a BD LSR-FORTESSA flow cytometer located in the flow cytometry core at the Pontificia Universidad Católica de Chile. For 445 AIM⁺CD4^{+,} and AIM⁺CD8⁺ T cells analyses, the percentage of DMSO was subtracted 446 from each stimulated sample to subtract the background. The positivity threshold for 447

AIM⁺CD4⁺ T cell stimulated with MP-S (0.174%) and MP-S+R (0.36%), as well as
AIM⁺CD8⁺ T cell stimulated with MP-CD8A+B (0.66%) was calculated using the
median twofold standard deviation of each sample of the pre-immune group^{22,34}.
For ELISPOT. IFN-v was measured using a Immunospot[®] (#hIFNgIL-4M-10)

following the manufacturer's instructions. Plates were read in an Immunospot S6
Micro Analyzer. The positivity threshold for PBMCs stimulated with MP-S (19.31
#SFC) MP-S+R (41.48 #SFC), as well as PBMCs stimulated with MP-CD8A+B
(104.54 #SFC) was calculated using the median twofold standard deviation of each
sample of the pre-immune group.

457

458 <u>Ethical considerations.</u>

The current study protocol was reviewed and approved by the Institutional Scientific Ethical Committee of Health Sciences at the Pontificia Universidad Católica de Chile (#200708006) and the trial was approved by the Chilean Public Health Institute (#24204/20) and conducted according to the current Tripartite Guidelines for Good Clinical Practices, the Declaration of Helsinki, and local regulations. Informed consent was obtained from all volunteers upon enrollment.

465

466 <u>Statistical analyses</u>

467 To statistically compare the neutralizing response against WT SARS-CoV-2, 468 ANOVA with the Geisser-Greenhouse correction test followed by Sidak multiple tests 469 were carried out on the log transformed data. Percentage of AIM⁺CD4⁺ and 470 AIM⁺CD8⁺ T cells and IFN- γ production by stimulated PBMCs against WT SARS-

471 CoV-2 were compared with a non-parametric Friedman test followed by a Dunn's
472 test for multiple comparisons. To compare the neutralizing and the cellular
473 responses against WT, Delta and Omicron, a two-way ANOVA test followed by a
474 Dunn's test for multiple comparisons was used.
475 The significance level was set at 0.05 for all the analyses. All data were analyzed

- 476 with GraphPad Prism 9.3.1.
- 477
- 478 Funding

The CoronaVac03CL Study was funded by The Ministry of Health, Government of 479 480 Chile, the Confederation of Production and Commerce (CPC), Chile and SINOVAC 481 Biotech. NIH NIAID, under Contract 75N93021C00016, supports AS and Contract 75N9301900065 supports AS, AG and DW. The Millennium Institute on Immunology 482 and Immunotherapy, Agencia Nacional de Investigación y Desarrollo (ANID) 483 - Millennium Science Initiative Program - ICN09 016 / ICN 484 485 2021 045: Millennium Institute on Immunology and Immunotherapy (ICN09_016 / ICN 2021_045; former P09/016-F) supports SMB, KA, PAG and AMK; 486 The Innovation Fund for Competitiveness FIC-R 2017 (BIP Code: 30488811-0) 487 488 supports SMB, PAG and AMK.

489

490 **Competing interests**

GZ and WM are SINOVAC Biotech employees and contributed to the
conceptualization of the study (clinical protocol and eCRF design) and did not
participate in the analysis or interpretation of the data presented in the manuscript.
A.S. is a consultant for Gritstone Bio, Flow Pharma, ImmunoScape, Moderna,

AstraZeneca, Avalia, Fortress, Repertoire, Gilead, Gerson Lehrman Group,
RiverVest, MedaCorp, and Guggenheim. La Jolla Institute for Immunology (LJI) has
filed for patent protection for various aspects of T cell epitope and vaccine design
work. All other authors declare no conflict of interest.

499

500 Acknowledgments

501 We would like to thank the support of the Ministry of Health, Government of Chile: Ministry of Science, Technology, Knowledge, and Innovation, Government of Chile; 502 503 The Ministry of Foreign Affairs, Government of Chile, and the Chilean Public Health 504 Institute (ISP). We also would like to thank Rami Scharf, Jessica White, Jorge Flores 505 and Miren Iturriza-Gomara from PATH for their active support in experimental design 506 and scientific discussion. We also thank the Vice Presidency of Research (VRI), the 507 Direction of Technology Transfer and Development (DTD) and the Legal Affairs Department (DAJ) of the Pontificia Universidad Católica de Chile. We are grateful to 508 509 the Administrative Directions of the School of Biological Sciences and the School of Medicine of the Pontificia Universidad Católica de Chile for their administrative 510 support. We would also like to thank to the members of the independent data safety 511 512 monitoring committee (members in the SA) for their oversight, and finally to the 513 subjects enrolled in the study for their participation and commitment with this trial. 514 This project has been funded in whole or in part with Federal funds from the National 515 Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021C00016 to A.S. and 516 Contract No. 75N93019C00065 to A.S and D.W. 517

518

519 Author contributions.

- 520 **Conceptualization**: AMK, KA, SMB, PAG, JVG, GZ, WM, FM-G, CM, HFP, BMS.
- 521 **Visualization:** AMK, KA, SMB, PAG, JVG, GZ, WM.
- 522 Methodology and research: FM-G, CM, HFP, BMS, AP-I, MR, DM-T, PP-S, DL,
- 523 CO, CC, NMSG, JAS, LFD, DR-P, YV, AC, SB, CI, MU, MSN, AR, RF, JF, JM, ER,
- 524 AG-A, MA, FV-E, RS-R, DW, AG, AS, GZ, WM, JVG-A
- 525 Data analysis: FM-G, CM, HFP, BMS, AP-I, MR, DM-T, LFD, AG-A, MA, FV-E, RS-
- 526 R
- 527 **Funding acquisition:** AMK, SMB.
- 528 **Project administration:** AMK, KA, SMB, PAG.
- 529 **Supervision:** AMK, KA, SMB, PAG.
- 530 Writing original draft: FM-G, CM, HFP, BMS.
- 531 Writing review & editing: AMK, SMB, PAG, FM-G, CM, HFP, BMS.
- 532 Verifying underlying data: AMK, SMB, FM-G, CM, HFP, BMS.
- 533
- 534 Members of the CoronaVac03CL study group are listed in the supplementary
- 535 material
- 536

537 References.

- Planas, D., Saunders, N., Maes, P., Guivel-Benhassine, F., Planchais, C., Buchrieser,
 J., Bolland, W.H., Porrot, F., Staropoli, I., Lemoine, F., et al. (2022). Considerable
 escape of SARS-CoV-2 Omicron to antibody neutralization. Nature *602*, 671-675.
 10.1038/s41586-021-04389-z.
- Levin, E.G., Lustig, Y., Cohen, C., Fluss, R., Indenbaum, V., Amit, S., Doolman, R.,
 Asraf, K., Mendelson, E., Ziv, A., et al. (2021). Waning Immune Humoral Response to
 BNT162b2 Covid-19 Vaccine over 6 Months. N Engl J Med 385, e84.
 10.1056/NEJMoa2114583.
- 5463.Nagy, A., and Alhatlani, B. (2021). An overview of current COVID-19 vaccine547platforms. Comput Struct Biotechnol J 19, 2508-2517. 10.1016/j.csbj.2021.04.061.
- Magen, O., Waxman, J.G., Makov-Assif, M., Vered, R., Dicker, D., Hernan, M.A.,
 Lipsitch, M., Reis, B.Y., Balicer, R.D., and Dagan, N. (2022). Fourth Dose of BNT162b2
 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med *386*, 1603-1614.
 10.1056/NEJMoa2201688.
- 5. Reyes, H., Diethelm-Varela, B., Mendez, C., Rebolledo-Zelada, D., Lillo-Dapremont,
 B., Munoz, S.R., Bueno, S.M., Gonzalez, P.A., and Kalergis, A.M. (2022). Contribution
 of Two-Dose Vaccination Toward the Reduction of COVID-19 Cases, ICU
 Hospitalizations and Deaths in Chile Assessed Through Explanatory Generalized
 Additive Models for Location, Scale, and Shape. Front Public Health *10*, 815036.
 10.3389/fpubh.2022.815036.
- Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z.,
 et al. (2020). Development of an inactivated vaccine candidate for SARS-CoV-2.
 Science *369*, 77-81. 10.1126/science.abc1932.
- Chen, Z., Zheng, W., Wu, Q., Chen, X., Peng, C., Tian, Y., Sun, R., Dong, J., Wang, M.,
 Zhou, X., et al. (2022). Global diversity of policy, coverage, and demand of COVID-19
 vaccines: a descriptive study. BMC Med *20*, 130. 10.1186/s12916-022-02333-0.
- Tanriover, M.D., Doganay, H.L., Akova, M., Guner, H.R., Azap, A., Akhan, S., Kose, S.,
 Erdinc, F.S., Akalin, E.H., Tabak, O.F., et al. (2021). Efficacy and safety of an
 inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a
 double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet *398*,
 213-222. 10.1016/S0140-6736(21)01429-X.
- Han, B., Song, Y., Li, C., Yang, W., Ma, Q., Jiang, Z., Li, M., Lian, X., Jiao, W., Wang, L.,
 et al. (2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2
 vaccine (CoronaVac) in healthy children and adolescents: a double-blind,
 randomised, controlled, phase 1/2 clinical trial. Lancet Infect Dis *21*, 1645-1653.
 10.1016/S1473-3099(21)00319-4.
- Seyahi, E., Bakhdiyarli, G., Oztas, M., Kuskucu, M.A., Tok, Y., Sut, N., Ozcifci, G.,
 Ozcaglayan, A., Balkan, II, Saltoglu, N., et al. (2021). Antibody response to inactivated
 COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study
 among hospital workers and elderly. Rheumatol Int *41*, 1429-1440. 10.1007/s00296 021-04910-7.

Jara, A., Undurraga, E.A., Gonzalez, C., Paredes, F., Fontecilla, T., Jara, G., Pizarro, A.,
 Acevedo, J., Leo, K., Leon, F., et al. (2021). Effectiveness of an Inactivated SARS-CoV Vaccine in Chile. N Engl J Med *385*, 875-884. 10.1056/NEJMoa2107715.

- Bueno, S.M., Abarca, K., Gonzalez, P.A., Galvez, N.M.S., Soto, J.A., Duarte, L.F.,
 Schultz, B.M., Pacheco, G.A., Gonzalez, L.A., Vazquez, Y., et al. (2021). Safety and
 Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in a Subgroup of Healthy
 Adults in Chile. Clin Infect Dis. 10.1093/cid/ciab823.
- Melo-Gonzalez, F., Soto, J.A., Gonzalez, L.A., Fernandez, J., Duarte, L.F., Schultz,
 B.M., Galvez, N.M.S., Pacheco, G.A., Rios, M., Vazquez, Y., et al. (2021). Recognition
 of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2
 Inactivated Vaccine. Front Immunol *12*, 747830. 10.3389/fimmu.2021.747830.
- Falsey, A.R., Frenck, R.W., Jr., Walsh, E.E., Kitchin, N., Absalon, J., Gurtman, A.,
 Lockhart, S., Bailey, R., Swanson, K.A., Xu, X., et al. (2021). SARS-CoV-2 Neutralization
 with BNT162b2 Vaccine Dose 3. N Engl J Med 385, 1627-1629.
 10.1056/NEJMc2113468.
- 15. Choi, A., Koch, M., Wu, K., Chu, L., Ma, L., Hill, A., Nunna, N., Huang, W., Oestreicher,
 J., Colpitts, T., et al. (2021). Safety and immunogenicity of SARS-CoV-2 variant mRNA
 vaccine boosters in healthy adults: an interim analysis. Nat Med *27*, 2025-2031.
 10.1038/s41591-021-01527-y.
- Pegu, A., O'Connell, S.E., Schmidt, S.D., O'Dell, S., Talana, C.A., Lai, L., Albert, J.,
 Anderson, E., Bennett, H., Corbett, K.S., et al. (2021). Durability of mRNA-1273
 vaccine-induced antibodies against SARS-CoV-2 variants. Science *373*, 1372-1377.
 10.1126/science.abj4176.
- Moreira, E.D., Jr., Kitchin, N., Xu, X., Dychter, S.S., Lockhart, S., Gurtman, A., Perez,
 J.L., Zerbini, C., Dever, M.E., Jennings, T.W., et al. (2022). Safety and Efficacy of a
 Third Dose of BNT162b2 Covid-19 Vaccine. N Engl J Med *386*, 1910-1921.
 10.1056/NEJMoa2200674.
- Schultz, B.M., Melo-Gonzalez, F., Duarte, L.F., Galvez, N.M.S., Pacheco, G.A., Soto,
 J.A., Berrios-Rojas, R.V., Gonzalez, L.A., Moreno-Tapia, D., Rivera-Perez, D., et al.
 (2022). A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells
 that Recognize Delta and Omicron Variants of Concern. mBio, e0142322.
 10.1128/mbio.01423-22.
- Regev-Yochay, G., Gonen, T., Gilboa, M., Mandelboim, M., Indenbaum, V., Amit, S.,
 Meltzer, L., Asraf, K., Cohen, C., Fluss, R., et al. (2022). Efficacy of a Fourth Dose of
 Covid-19 mRNA Vaccine against Omicron. N Engl J Med *386*, 1377-1380.
 10.1056/NEJMc2202542.
- Duarte, L.F., Galvez, N.M.S., Iturriaga, C., Melo-Gonzalez, F., Soto, J.A., Schultz, B.M.,
 Urzua, M., Gonzalez, L.A., Vazquez, Y., Rios, M., et al. (2021). Immune Profile and
 Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARSCoV-2 Vaccine. Front Immunol *12*, 742914. 10.3389/fimmu.2021.742914.
- Abarca, K., Iturriaga, C., Urzua, M., Le Corre, N., Pineda, A., Fernandez, C.,
 Dominguez, A., Gonzalez, P.A., Bueno, S.M., Donato, P., et al. (2022). Safety and
 Non-Inferiority Evaluation of Two Immunization Schedules with an Inactivated SARS-

622 CoV-2 Vaccine in Adults: A Randomized Clinical Trial. Vaccines (Basel) *10*. 623 10.3390/vaccines10071082.

- Grifoni, A., Weiskopf, D., Ramirez, S.I., Mateus, J., Dan, J.M., Moderbacher, C.R.,
 Rawlings, S.A., Sutherland, A., Premkumar, L., Jadi, R.S., et al. (2020). Targets of T
 Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and
 Unexposed Individuals. Cell *181*, 1489-1501 e1415. 10.1016/j.cell.2020.05.015.
- Arbel, R., Sergienko, R., Friger, M., Peretz, A., Beckenstein, T., Yaron, S., Netzer, D.,
 and Hammerman, A. (2022). Effectiveness of a second BNT162b2 booster vaccine
 against hospitalization and death from COVID-19 in adults aged over 60 years. Nat
 Med 28, 1486-1490. 10.1038/s41591-022-01832-0.
- Tuekprakhon, A., Nutalai, R., Dijokaite-Guraliuc, A., Zhou, D., Ginn, H.M., Selvaraj,
 M., Liu, C., Mentzer, A.J., Supasa, P., Duyvesteyn, H.M.E., et al. (2022). Antibody
 escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell *185*, 2422-2433 e2413. 10.1016/j.cell.2022.06.005.
- Hurme, A., Jalkanen, P., Heroum, J., Liedes, O., Vara, S., Melin, M., Terasjarvi, J., He,
 Q., Poysti, S., Hanninen, A., et al. (2022). Long-Lasting T Cell Responses in BNT162b2
 COVID-19 mRNA Vaccinees and COVID-19 Convalescent Patients. Front Immunol *13*,
 869990. 10.3389/fimmu.2022.869990.
- Tarke, A., Coelho, C.H., Zhang, Z., Dan, J.M., Yu, E.D., Methot, N., Bloom, N.I.,
 Goodwin, B., Phillips, E., Mallal, S., et al. (2022). SARS-CoV-2 vaccination induces
 immunological T cell memory able to cross-recognize variants from Alpha to
 Omicron. Cell *185*, 847-859 e811. 10.1016/j.cell.2022.01.015.
- Zhang, Z., Mateus, J., Coelho, C.H., Dan, J.M., Moderbacher, C.R., Galvez, R.I., Cortes,
 F.H., Grifoni, A., Tarke, A., Chang, J., et al. (2022). Humoral and cellular immune
 memory to four COVID-19 vaccines. Cell *185*, 2434-2451 e2417.
 10.1016/j.cell.2022.05.022.
- Escobar, A., Reyes-Lopez, F.E., Acevedo, M.L., Alonso-Palomares, L., ValienteEcheverria, F., Soto-Rifo, R., Portillo, H., Gatica, J., Flores, I., Nova-Lamperti, E., et al.
 (2021). Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule
 Vaccination in a Healthy Population Group. Front Immunol *12*, 766278.
 10.3389/fimmu.2021.766278.
- Mok, C.K.P., Cohen, C.A., Cheng, S.M.S., Chen, C., Kwok, K.O., Yiu, K., Chan, T.O., Bull,
 M., Ling, K.C., Dai, Z., et al. (2022). Comparison of the immunogenicity of BNT162b2
 and CoronaVac COVID-19 vaccines in Hong Kong. Respirology 27, 301-310.
 10.1111/resp.14191.
- 857 30. Reynolds, C.J., Swadling, L., Gibbons, J.M., Pade, C., Jensen, M.P., Diniz, M.O.,
 858 Schmidt, N.M., Butler, D.K., Amin, O.E., Bailey, S.N.L., et al. (2020). Discordant
 859 neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2
 860 infection. Sci Immunol 5. 10.1126/sciimmunol.abf3698.
- Galipeau, Y., Siragam, V., Laroche, G., Marion, E., Greig, M., McGuinty, M., Booth,
 R.A., Durocher, Y., Cuperlovic-Culf, M., Bennett, S.A.L., et al. (2021). Relative Ratios
 of Human Seasonal Coronavirus Antibodies Predict the Efficiency of CrossNeutralization of SARS-CoV-2 Spike Binding to ACE2. EBioMedicine 74, 103700.
 10.1016/j.ebiom.2021.103700.

Beltran-Pavez, C., Riquelme-Barrios, S., Oyarzun-Arrau, A., Gaete-Argel, A.,
Gonzalez-Stegmaier, R., Cereceda-Solis, K., Aguirre, A., Travisany, D., Palma-Vejares,
R., Barriga, G.P., et al. (2021). Insights into neutralizing antibody responses in
individuals exposed to SARS-CoV-2 in Chile. Sci Adv 7. 10.1126/sciadv.abe6855.

- 33. Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., Han, W., Chen, Z., Tang, R., Yin, W.,
 et al. (2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2
 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial. Lancet Infect Dis *21*, 181-192. 10.1016/S14733099(20)30843-4.
- Ban, J.M., Mateus, J., Kato, Y., Hastie, K.M., Yu, E.D., Faliti, C.E., Grifoni, A., Ramirez,
 S.I., Haupt, S., Frazier, A., et al. (2021). Immunological memory to SARS-CoV-2
 assessed for up to 8 months after infection. Science *371*. 10.1126/science.abf4063.
- 678

679

680 Figure legends.

681

Figure 1. Study profile, vaccination scheme and sampling, enrolled volunteers. 682 and cohort included in the study. (A) Schematic representation and sample 683 684 distribution of performed experiments. From a total of 138 individuals that received 685 two booster doses of CoronaVac®, the neutralizing antibodies were analyzed in 686 blood samples from 87 volunteers by surrogate virus neutralization test (sVNT), 63 by conventional virus neutralization test (cVNT) and 60 by Pseudovirus-based 687 neutralization assay (pVNT). sVNT and pVNT were used to evaluate the neutralizing 688 689 response induced by a second booster dose against the Delta and/or the Omicron 690 variants. Cellular immunity was analyzed in blood samples from 46 volunteers at each time point. (B) Blood sampling times, before the first vaccination/pre-immune 691 (T1), at 4 weeks (+3 weeks) after the second dose (T2), before the administration of 692 the third dose (-9 weeks) (T3), at 4 weeks (-1/+2 weeks) after the third dose (T4), 693 before the administration of the fourth dose (-9 weeks) (T5) and at 4 weeks (+5 694 695 weeks) after the fourth dose (T6), and vaccination schedule.

696

697 Figure 2. Humoral response of volunteers who received a second booster dose

of CoronaVac[®]. The neutralizing capacity of circulating antibodies in adults was
evaluated in Blood samples collected before the first vaccination/pre-immune (T1),
at 4 weeks (+3 weeks) after the second dose (T2), before the administration of the
third dose (-9 weeks) (T3), at 4 weeks (-1/+2 weeks) after the third dose (T4), before
the administration of the fourth dose (-9 weeks) (T5) and at 4 weeks (+5 weeks) after
the fourth dose (T6), and vaccination schedule. (A) Neutralizing capacity of

circulating antibodies against SARS-CoV-2 in serum of 87 volunteers was 704 705 determined by a surrogate Viral Neutralization Test (sVNT) expressed as IU/ml. (B) 706 Reciprocal dilution of sera required to prevent in vitro infection obtained sera from 63 adults required to prevent in vitro infection of Hela Cells. Numbers on top of each 707 708 data set represents the GMT, and horizontal lines represent the 95% CI. (C) 709 Geometric mean titter (GMTs) of neutralizing antibodies against the WT-spike. Delta-710 spike and Omicron-spike proteins detected in the serum of 87 volunteers immunized 711 with CoronaVac® through sVNT. Dashed line: limit of detection. Red values under 712 the significance line: indicate a decrease in the means of the two compared time 713 points; Blue values: indicate an increase in the means of the two compared time 714 points. (A-B) Data was analyzed with ANOVA with the Geisser-Greenhouse 715 correction test followed by a post-hoc Sidak multiple test. *P<0.05; **P<0.01; 716 ***P<0.001; ****P<0.0001. (C) Two-way ANOVA test followed by a post-hoc Dunn's multiple test. *P<0.05; **P<0.01; ***P<0.001, ****P<0.0001. 717

718

719 Figure 3. Cellular response of volunteers that received a second booster dose of CoronaVac[®]. Cellular response in adults was evaluated in PBMCs collected 720 721 before the first vaccination/pre-immune (T1), at 4 weeks (+3 weeks) after the second 722 dose (T2), before the administration of the third dose (-9 weeks) (T3), at 4 weeks (-723 1/+2 weeks) after the third dose (T4), before the administration of the fourth dose (-724 9 weeks) (T5) and at 4 weeks (+5 weeks) after the fourth dose (T6), and vaccination schedule. (A) The percentage of AIM+ (OX40+CD137+) CD4+ T cells and (B) AIM+ 725 (CD69+CD137+) CD8+ T cells was determined in PBMCs of 46 adult volunteers by 726 727 flow cytometry. PBMCs were stimulated for 24h with mega-pools of peptides derived

from proteins of WT SARS-CoV-2. The number of IFN-g producing SFCs was 728 729 determined by ELISPOT upon stimulation for 48h with mega-pools of (C) S+R peptides or with (D) CD8A+B peptides. (E) The percentage of AIM+ 730 (OX40+CD137+) CD4+ T cells from PBMCs of 46 adult volunteers were analyzed 731 732 by flow cytometry after the stimulation for 24h with mega-pools of peptides derived 733 from the Spike protein of the WT SARS-CoV-2, the Delta and the Omicron variants. 734 (F) The number of IFN-g producing SFCs was determined by ELISPOT assays 735 PBMCs of 46 adult volunteers were analyzed by flow cytometry after the stimulation 736 for 48h with mega-pools of peptides derived from the Spike protein of the WT SARS-737 CoV-2, the Delta and the Omicron variants. Horizontal lines represent mean and 738 95% CI. Flow cytometry data was normalized against the DMSO control. (A-D) Data 739 was analyzed using a non-parametric Friedman test followed by a post-hoc Dunn's 740 test for multiple comparisons. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. (E-F) Two-way ANOVA test followed by a post-hoc Dunn's multiple test. *P<0.05; 741 **P<0.01; ***P<0.001, ****P<0.0001. 742

743

744

745





А





С













Table v feri Frequency of volunteers with detectable value of the sponse against WT (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. SARS-CoV-2 It is made available under a CC-BY-NC-ND 4.0 International license.

Methodology	Indicators Cellular	T1	T2	Т3	T4	T5	Т6
	positivity						
Flow cytometry	CD4+AIM+(OX40+CD13)	6/46	16/46	23/46	30/46	19/46	21/46
	%	13.0	34.8	50.0	65.2	41.3	45.7
	CD8+AIM+(CD69+CD13)	6/46	16/46	10/46	16/46	10/46	12/46
	%	13.0	34.8	21.7	34.8	21.7	26.1
ELISPOT	IFN-γ ⁺ SFC MP-S+R	8/46	22/46	21/46	31/46	24/46	23/46
	%	17.4	47.8	45.7	67.4	52.2	50
	IFN-γ⁺ SFC MP-	2/46	3/46	5/46	7/46	8/46	6/46
	CD8A+B						
	%	4.3	6.5	10.9	15.2	17.4	13.0

AIM: Activation-Induced-Marker; SFC: Spot Forming Cells; MP-S: Spike megapool of peptides